Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

Affiliation auteurs!!!! Error affiliation !!!!
TitreAnalysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx
Type de publicationJournal Article
Year of Publication2020
AuteursThurner L., Poeschel V, Haioun C., Houot R., Gaulard P., Molina T., Rosenwald A., Andre M., Hoffmann J., Dreyling M., Casasnovas O., Maisonneuve H., Tilly H., Illmer T., Mayer S., Kirchen H., La Rosee P., Loeffler M., Ziepert M., Altmann B., Held G.
JournalONCOLOGY RESEARCH AND TREATMENT
Volume43
Pagination60-61
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN2296-5270